Aktien Sensor

Sanofi SA’s stock price declined 1.76% on April 22, following a 7.42% drop in March, but analysts remain optimistic about the company’s prospects.

Sanofi’s stock price has stabilized at 103.4 EUR, but experts warn that this is a temporary reprieve from the company’s inherently volatile nature.

Sanofi has established a new research and development unit in France to accelerate vaccine development and mRNA technology, while also receiving approval for its Dupixent treatment in the US.

Sanofi’s stock price has surged as investors recognize the company’s growing momentum, driven by promising research and development efforts, particularly with its Tolebrutinib treatment for multiple sclerosis.

Sanofi has made a $1.9 billion bet on a bispecific myeloid cell engager treatment for autoimmune diseases, a high-stakes gamble that could revolutionize the immunology market or leave the company reeling from a costly misstep.